July 29 2013
Fagron Inc. has confirmed via the PBM responsible for TRICARE that TRICARE is evaluating the issue of pharmaceutical compounds and will delay the implementation of any change in practice on compounded prescriptions for 180 days.
The ESI/TRICARE web site now has the following message:
"TRICARE is evaluating the issue of pharmaceutical compounds. We are working to ensure both excellent and safe care for our beneficiaries and clear communication with our providers and beneficiaries. To assure success in both of these efforts, TRICARE will delay the implementation of any change in practice on compounded prescriptions for 180 days. Compounded prescriptions are tailored for individuals by pharmacists. These prescriptions may contain both conventional medications and other ingredients. Many of the included ingredients are not FDA approved. Those compound prescriptions which contain ingredients that are not FDA approved are the ones that TRICARE is concerned about.”
Fagron, Inc., would like to thank our customers for their efforts to inform patients, physicians, military ranking members and elected officials of these changes.